xanthine has been researched along with Asthma in 9 studies
7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.
9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
Excerpt | Relevance | Reference |
---|---|---|
"The effect of aminophylline administered intravenously in dose 250 mg on plasma oxypurines (hypoxanthine and xanthine) concentration as well as on plasma adenosine deaminase activity and plasma AMP deaminase activity was studied in 17 patients with bronchial asthma or chronic cor pulmonale." | 7.68 | [The effect of aminophylline on plasma oxypurines in patients with bronchial asthma or cor pulmonale]. ( Banaszak, F; Głuszek, J; Tykarski, A, 1991) |
"The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients." | 5.06 | Effect of theophylline and enprofylline on bronchial hyperresponsiveness. ( Boorsma, M; Jonkman, JH; Koëter, GH; Kraan, J; van der Mark, TW, 1989) |
"The effect of aminophylline administered intravenously in dose 250 mg on plasma oxypurines (hypoxanthine and xanthine) concentration as well as on plasma adenosine deaminase activity and plasma AMP deaminase activity was studied in 17 patients with bronchial asthma or chronic cor pulmonale." | 3.68 | [The effect of aminophylline on plasma oxypurines in patients with bronchial asthma or cor pulmonale]. ( Banaszak, F; Głuszek, J; Tykarski, A, 1991) |
"Xanthine was still the most frequently used medication for asthmatic patients (60." | 1.42 | Analysis of prescription pattern and guideline adherence in the management of asthma among medical institutions and physician specialties in Taiwan between 2000 and 2010. ( Chen, TJ; Chou, CL; Chou, YC; Lin, AM; Lin, TL; Perng, DW; Wu, MS, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (33.33) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 3 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Basu, S | 1 |
Barawkar, DA | 1 |
Ramdas, V | 1 |
Patel, M | 1 |
Waman, Y | 1 |
Panmand, A | 1 |
Kumar, S | 1 |
Thorat, S | 1 |
Naykodi, M | 1 |
Goswami, A | 1 |
Reddy, BS | 1 |
Prasad, V | 1 |
Chaturvedi, S | 1 |
Quraishi, A | 1 |
Menon, S | 1 |
Paliwal, S | 1 |
Kulkarni, A | 1 |
Karande, V | 1 |
Ghosh, I | 1 |
Mustafa, S | 1 |
De, S | 1 |
Jain, V | 1 |
Banerjee, ER | 1 |
Rouduri, SR | 1 |
Palle, VP | 1 |
Chugh, A | 1 |
Mookhtiar, KA | 1 |
Albers, FC | 1 |
Price, RG | 1 |
Smith, SG | 1 |
Yancey, SW | 1 |
Chou, CL | 1 |
Perng, DW | 1 |
Lin, TL | 1 |
Lin, AM | 1 |
Chen, TJ | 1 |
Wu, MS | 1 |
Chou, YC | 1 |
CASS, LJ | 1 |
FREDERIK, WS | 1 |
NELSON, LS | 1 |
STOESSER, AV | 1 |
Daly, JW | 1 |
Banaszak, F | 1 |
Głuszek, J | 1 |
Tykarski, A | 1 |
Anderson, HR | 1 |
Koëter, GH | 1 |
Kraan, J | 1 |
Boorsma, M | 1 |
Jonkman, JH | 1 |
van der Mark, TW | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma[NCT01691521] | Phase 3 | 580 participants (Actual) | Interventional | 2012-10-08 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
FEV1 is defined as the volume of air expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using mixed model repeated measures with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), treatment and visit, plus interaction terms for visit by baseline and visit by treatment group. (NCT01691521)
Timeframe: Baseline, Week 32
Intervention | Milliliters (mL) (Least Squares Mean) |
---|---|
Placebo | 86 |
Mepolizumab 75 mg IV | 186 |
Mepolizumab 100 mg SC | 183 |
The St. George's Respiratory Questionnaire is an established instrument, comprising 50 questions, evaluating symptoms, activity, and impacts; to measure Quality of Life in participants with diseases of airway obstruction and to elicit the participant's opinion of his/her health. The lowest possible value is zero and the highest possible value is 100. The higher values correspond to greater impairment in quality of life. The questionnaire was administered at Baseline (Visit 2) and at the Exit Visit (approximately 4 weeks after the last dose of study treatment). The change from baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using analysis of covariance with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), baseline % predicted FEV1, and treatment. (NCT01691521)
Timeframe: Baseline, Week 32
Intervention | Scores on a scale (Least Squares Mean) |
---|---|
Placebo | -9.0 |
Mepolizumab 75 mg IV | -15.4 |
Mepolizumab 100 mg SC | -16.0 |
Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. (NCT01691521)
Timeframe: From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose
Intervention | Number of exacerbations per year (Number) |
---|---|
Placebo | 1.74 |
Mepolizumab 75 mg IV | 0.93 |
Mepolizumab 100 mg SC | 0.83 |
Clinically significant exacerbations of asthma is defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. (NCT01691521)
Timeframe: From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose
Intervention | Number of exacerbations per year (Number) |
---|---|
Placebo | 0.10 |
Mepolizumab 75 mg IV | 0.06 |
Mepolizumab 100 mg SC | 0.03 |
Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. (NCT01691521)
Timeframe: From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose
Intervention | Number of exacerbations per year (Number) |
---|---|
Placebo | 0.20 |
Mepolizumab 75 mg IV | 0.14 |
Mepolizumab 100 mg SC | 0.08 |
1 review available for xanthine and Asthma
Article | Year |
---|---|
Caffeine analogs: biomedical impact.
Topics: Alzheimer Disease; Asthma; Biomedical Research; Caffeine; Calcium; Central Nervous System Stimulants | 2007 |
2 trials available for xanthine and Asthma
Article | Year |
---|---|
Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Anti-Asthmatic Agents; Antibodies, Mon | 2017 |
Effect of theophylline and enprofylline on bronchial hyperresponsiveness.
Topics: Adult; Airway Resistance; Asthma; Bronchi; Bronchial Provocation Tests; Bronchodilator Agents; Doubl | 1989 |
6 other studies available for xanthine and Asthma
Article | Year |
---|---|
Design and synthesis of novel xanthine derivatives as potent and selective A
Topics: Adenosine A2 Receptor Antagonists; Animals; Asthma; Dogs; Drug Design; Hep G2 Cells; Humans; Madin D | 2017 |
Analysis of prescription pattern and guideline adherence in the management of asthma among medical institutions and physician specialties in Taiwan between 2000 and 2010.
Topics: Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Ambulatory Care; Anti-Asthmatic | 2015 |
A new xanthine derivative: theophylline with diethylenediamine; a clinical study.
Topics: Asthma; Biomedical Research; Piperazines; Theophylline; Xanthine; Xanthines | 1958 |
CLINICAL ADVANTAGES OF ISOEPHEDRINE OVER EPHEDRINE WITH XANTHINE DERIVATIVES AND EXPECTORANTS IN MILD AND MODERATELY SEVERE ASTHMA.
Topics: Adolescent; Asthma; Diuretics; Drug Therapy; Ephedrine; Expectorants; Geriatrics; Glycerol; Guaiacol | 1964 |
[The effect of aminophylline on plasma oxypurines in patients with bronchial asthma or cor pulmonale].
Topics: Adult; Aminophylline; Asthma; Female; Humans; Hypoxanthine; Hypoxanthines; Male; Middle Aged; Pulmon | 1991 |
Trends and district variations in the hospital care of childhood asthma: results of a regional study 1970-85.
Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones | 1990 |